Zeit für ein Browserupdate

IE6 not supported.

Keine sichere Verbindung.

no ssl-connection established.


Kopfbereich

Logo

THIS INFORMATION IS FOR NON-US HEALTHCARE PROVIDERS ONLY

Hauptnavigation

The CONTINUATION-PV Study

Is an open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously participated in the PROUD-PV study.

Patients who received AOP2014 or Hydroxyurea (HU) and completed the PROUD-PV study, will be included in this CONTINUATION-PV study. After having signed the informed consent form (ICF), eligible patients will be enrolled.

Patients on Ropeginterferon α-2b (AOP2014)  will receive study medication at a dosing scheme of every 2,3, or 4 weeks in order to achieve optimal disease response. 

The best available treatment (BAT) arm receives standard first line treatment for treatment of PV disease, as per investigator’s discretion. Disease response assessments will be made every three months by the investigator to allow continuous data assessment.

Find more information about the CONTINUATION-PV study on clinicaltrials.gov …